ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.

Authors

• G H Su
• R Bansal
• K M Murphy
• E Montgomery
• C J Yeo
• R H Hruban
• S E Kern

Publication/Presentation Date

3-13-2001

Abstract

DPC4 is known to mediate signals initiated by type beta transforming growth factor (TGFbeta) as well as by other TGFbeta superfamily ligands such as activin and BMP (bone morphogenic proteins), but mutational surveys of such non-TGFbeta receptors have been negative to date. Here we describe the gene structure and novel somatic mutations of the activin type I receptor, ACVR1B, in pancreatic cancer. ACVR1B has not been described previously as a mutated tumor-suppressor gene.

Volume

98

Issue

6

First Page

3254

Last Page

3257

ISSN

0027-8424

Published In/Presented At

Su, G. H., Bansal, R., Murphy, K. M., Montgomery, E., Yeo, C. J., Hruban, R. H., & Kern, S. E. (2001). ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 98(6), 3254–3257. https://doi.org/10.1073/pnas.051484398

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

11248065

Department(s)

Administration and Leadership

Document Type

Article